TG Therapeutics IncNASDAQ:TGTX
- LAST PRICE18.5950
- TODAY'S CHANGE (%)0.8050 (4.5250%)
- Bid / Lots18.5800/ 2
- Ask / Lots18.6100/ 1
- Open / Previous Close17.6700 / 17.7900
- Day Range
- 52 Week Range
- Volume918,454
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TGTX |
|---|---|---|
| 09:32 ET | 20048 | 17.59 |
| 09:34 ET | 7656 | 17.73 |
| 09:36 ET | 64957 | 17.93 |
| 09:38 ET | 14890 | 18.1599 |
| 09:39 ET | 34276 | 18.375 |
| 09:41 ET | 33401 | 18.43 |
| 09:43 ET | 42448 | 18.39 |
| 09:45 ET | 12952 | 18.33 |
| 09:48 ET | 19899 | 18.27 |
| 09:50 ET | 5983 | 18.33 |
| 09:52 ET | 5488 | 18.31 |
| 09:54 ET | 10998 | 18.35 |
| 09:56 ET | 13978 | 18.4 |
| 09:57 ET | 720 | 18.3723 |
| 09:59 ET | 3742 | 18.42 |
| 10:01 ET | 26219 | 18.481 |
| 10:03 ET | 4405 | 18.38 |
| 10:06 ET | 1293 | 18.375 |
| 10:08 ET | 11536 | 18.4801 |
| 10:10 ET | 36944 | 18.56 |
| 10:12 ET | 10509 | 18.375 |
| 10:14 ET | 15178 | 18.41 |
| 10:15 ET | 11145 | 18.46 |
| 10:17 ET | 2826 | 18.42 |
| 10:19 ET | 5414 | 18.43 |
| 10:21 ET | 2851 | 18.435 |
| 10:24 ET | 8155 | 18.51 |
| 10:26 ET | 7575 | 18.5 |
| 10:28 ET | 1485 | 18.52 |
| 10:30 ET | 8462 | 18.53 |
| 10:32 ET | 1325 | 18.495 |
| 10:33 ET | 6584 | 18.52 |
| 10:35 ET | 10603 | 18.54 |
| 10:37 ET | 2038 | 18.52 |
| 10:39 ET | 4424 | 18.52 |
| 10:42 ET | 7217 | 18.48 |
| 10:44 ET | 8140 | 18.5407 |
| 10:46 ET | 5066 | 18.51 |
| 10:48 ET | 26436 | 18.62 |
| 10:50 ET | 10070 | 18.56 |
| 10:51 ET | 7675 | 18.63 |
| 10:53 ET | 25603 | 18.7127 |
| 10:55 ET | 10309 | 18.72 |
| 10:57 ET | 15574 | 18.79 |
| 11:00 ET | 18354 | 18.86 |
| 11:02 ET | 11836 | 18.855 |
| 11:04 ET | 8923 | 18.82 |
| 11:06 ET | 13787 | 18.8 |
| 11:08 ET | 11323 | 18.805 |
| 11:09 ET | 14001 | 18.88 |
| 11:11 ET | 13127 | 18.86 |
| 11:13 ET | 8866 | 18.85 |
| 11:15 ET | 8281 | 18.81 |
| 11:18 ET | 2856 | 18.86 |
| 11:20 ET | 8057 | 18.82 |
| 11:22 ET | 10673 | 18.8278 |
| 11:24 ET | 2910 | 18.795 |
| 11:26 ET | 4738 | 18.795 |
| 11:27 ET | 5646 | 18.7895 |
| 11:29 ET | 3022 | 18.8 |
| 11:31 ET | 7531 | 18.7128 |
| 11:33 ET | 3888 | 18.6553 |
| 11:36 ET | 16715 | 18.61 |
| 11:38 ET | 1833 | 18.595 |
Jun 11, 2024
Jun 7, 2024
TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference, from 7:50AM ET on Friday Jun 07, 2024 by Dow Jones
7:50AM ET on Friday Jun 07, 2024 by Dow Jones
Jun 3, 2024
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference, from 7:30AM ET on Monday Jun 03, 2024 by Dow Jones
7:30AM ET on Monday Jun 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
TG Therapeutics Inc | 2.7B | 84.3x | --- |
Twist Bioscience Corp | 2.9B | -15.1x | --- |
ADMA Biologics Inc | 2.6B | -562.5x | --- |
MorphoSys AG | 2.7B | -5.4x | --- |
Arrowhead Pharmaceuticals Inc | 3.2B | -6.1x | --- |
Vericel Corp | 2.2B | 4,775.1x | --- |
Company Information
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Contact Information
- Headquarters
- 3020 Carrington Mill Blvd., Suite 475MORRISVILLE, NC, United States 27560-5435
- Phone
- 212-554-4484
- Fax
- 212-554-4531
Executives
- Chairman of the Board, President, Chief Executive Officer
- Michael Weiss
- Chief Financial Officer, Treasurer, Corporate Secretary
- Sean Power
- Lead Independent Director
- Laurence Charney
- Independent Director
- Yann Echelard
- Independent Director
- Kenneth Hoberman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
|---|---|
Revenue (TTM) | $289.3M |
Shares Outstanding | 154.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.23 |
EPS | $0.22 |
Book Value | $1.06 |
P/E Ratio | 84.3x |
Price/Sales (TTM) | 9.5 |
Price/Cash Flow (TTM) | 66.5x |
Operating Margin | 16.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
